Myelodysplastic Syndromes Clinical Trials
Not all trials are listed on www.ClinicalTrials.gov. The investigators may have chosen not to register the trial, or the study may not be eligible to be listed on ClinicalTrials.gov. If the study has not, for example, been approved by a human subject review board, it cannot be posted. Some trials are not listed because the investigators are not planning to publish the research findings, so you can ask the study coordinator why the study has not been included on ClinicalTrials.gov before you give your consent to participate.
The information on the studies linked below is provided strictly as a resource, not as an endorsement of any given treatment, doctor, or medical center.
Remember, before you sign a consent form, Clinical Trials Explained can help you understand the potential risks and benefits of a clinical trial. You can also contact the AA&MDSIF staff to discuss any questions you have at clinicaltrials@aamds.org or by calling the office at 301.279.7202 or 800.747.2820.
Last Modified: February 2009
Allogeneic Stem Cell Transplantation Followed by Targeted Immune Therapy in Average Risk Acute Myelogenous Leukemia/Myelodysplastic Syndrome/Juvenile Myelomonocytic Leukemia AML/MDS/JMML
Protocol 01-504 | New York, New York
View Details >>
Delayed Infusion of Ex Vivo Anergized Peripheral Blood Mononuclear Cells Following CD34 Selected Peripheral Blood Stem Cell Transplantation from Haploidentical Donor for Patients with Myelodysplasia
Protocol DFCI# 05-030 | Boston, Massachusetts
View Details >>
Fludarabine and Melphalan Followed by Healthy Donor Stem Cell Transplantation for Hematologic Malignancies
Protocol 121 | Philadelphia, Pennsylvania
View Details >>
Radiolabeled BC8 (anti-CD-45) Antibody Combined with Cyclophosphamide and Total Body Irradiation Followed by HLA-Matched Related or Unrelated Stem Cell Transplantation as Treatment for Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome
Protocol FHCRC #1297 | Seattle, Washington
View Details >>
Phase II Study of Combination of Thymoglobulin, Cyclosporine, Methylprednisone, and GCSF in Patients with Newly Diagnosed Aplastic Anemia or with Hypoplastic Myelodysplastic Syndrome
Protocol MDA 2005-0115 | Houston, Texas
View Details >>
A Phase I Combination Trial of SGN-33 (Anti-huCD33 mAb; HuM195; Lintuzumab) and Lenalidomide (Revlimid®) in Patients With Myelodysplastic Syndromes (MDS)
Protocol SG033-0002 WIRB Pr. No.: 20070491 | Multiple Locations
View Details >>
A Phase I, Multi-Dose Study of SGN-33 (anti-huCD33 mAb;HuM195; lintuzumab) in Patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)
Protocol SG033-0001 | New York, New York
View Details >>